英特格拉生命科学——这家医疗科技公司再度确认其2026年度的业绩预期。该公司预计，有机营收将实现0.8%至3.3%的同比增长。与此同时，其调整后的每股收益（Adj EPS）目标区间也被锁定在2.40美元至2.50美元之间。这一最新的财务指引，彰显了管理层对业务前景的审慎乐观态度。
英特格拉生命科学——这家医疗科技公司再度确认其2026年度的业绩预期。该公司预计，有机营收将实现0.8%至3.3%的同比增长。与此同时，其调整后的每股收益（Adj EPS）目标区间也被锁定在2.40美元至2.50美元之间。这一最新的财务指引，彰显了管理层对业务前景的审慎乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.